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ABSTRACT
The array CGH technique (Array Comparative
Genome Hybridization) has been developed to detect
chromosomal copy number changes on a genome-
wide and/or high-resolution scale. It is used in
human genetics and oncology, with great promise
for clinical application. Until recently primarily PCR
amplified bacterial artificial chromosomes (BACs)
or cDNAs have been spotted as elements on the
array. The large-scale DNA isolations or PCR
amplifications of the large-insert clones necessary
for manufacturing the arrays are elaborate and
time-consuming. Lack of a high-resolution highly
sensitive (commercial) alternative has undoubtedly
hinderedtheimplementationofarrayCGHinresearch
and diagnostics. Recently, synthetic oligonuc-
leotides as arrayed elements have been introduced
as an alternative substrate for array CGH, both by
academic institutions as well as by commercial
providers. Oligonucleotide libraries or ready-made
arrays can be bought off-the-shelf saving consider-
able time and efforts. For RNA expression profiling,
we have seen a gradual transition from in-house prin-
tedcDNA-basedexpressionarraystooligonucleotide
arrays and we expect a similar transition for array
CGH. This review compares the different platforms
and will attempt to shine a light on the ‘BAC to the
future’ of the array CGH technique.
ARRAY CGH IMPROVES SPATIAL RESOLUTION
Classical comparative genomic hybridization provided the
possibility for detecting chromosomal copy number changes
in cell and tissue samples, similar to karyotyping, without the
need of culturing (1). Even formalin-ﬁxed parafﬁn-embedded
(FFPE) archival material could be analyzed, allowing for the
exploration of large clinical tissue archives (2–4). Yet, reso-
lution was limited and analysis required a high level of cyto-
genetic expertise. Array CGH was introduced in the late
nineties (4) and overcame these two major drawbacks. Several
excellent reviews have been written on the applications and
current status of array CGH of which we highly recommend
Pinkel and Alberston (5), among others (6–9).
The ﬁrst array CGH platforms generally used large-insert
clones, such as BAC (Bacterial Artiﬁcial Chromosomes),
YAC (Yeast Artiﬁcial Chromosomes) or PAC (P1-derived
Artiﬁcial Chromosomes) clones. Later, also the shorter cos-
mids and fosmids clones were introduced as spotted elements
(5), as well as 130–600 bp single-stranded DNA molecules
(10).Several laboratories usedcDNAarrays,initiallydesigned
for expression proﬁling, as an alternative for measuring chro-
mosomalcopynumberchanges(2).Eventhoughthisapproach
certainly has yielded valuable information, it cannot compete
with the current platforms in terms of its maximal achievable
resolution. Advantages and disadvantages of the cDNA plat-
form for array CGH are discussed in further detail by Davies
et al. (8). Until recently, commercial alternatives have had
very limited resolution, 3 Mb or less which is comparable
with conventional CGH (1,11,12). As a result of the lack of
widely accessible platforms, the possibilities of oligonuc-
leotides as spotted elements on the arrays have been success-
fully explored. Oligonucleotide array CGH (oaCGH) now
offers genome-covering resolution. To our knowledge, we
are the only group that developed both oaCGH (13–15) as
well as BAC-based array CGH (16–20), without a commercial
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doi:10.1093/nar/gkj456interest. This allows us to discuss the advantages and disad-
vantages of the respective platforms, which we will do in this
review. Reviews written so far are from laboratories that
mainly perform BAC array CGH. Our goal is to evaluate the
value of the different oaCGH platforms and compare it
with the BAC array CGH platform. To our opinion oaCGH,
and not BAC CGH arrays, is the platform that will prevail in
the future.
DIFFERENT ARRAY CGH PLATFORMS
The vast majority of array CGH data available today has been
generated using BAC CGH arrays. BACs vary in length from
150 to 200 kb and the DNA yield is generally low when
isolated from Escherichia coli (5). Since high DNA concen-
tration is mandatory for high quality results, most of the
platforms use PCR ampliﬁcation prior to spotting the arrays.
Genome-wide BAC arrays vary in size from 2400 to 30000
unique array elements. Difﬁculties when setting up BAC
arrays parallel those of spotted cDNA arrays in terms of
clone management and probe identity due to PCR contamina-
tions. In addition, BAC array data suffer from mapping inac-
curacies of the clones to the human genome. The venture for
the production of a BAC array with a 1 Mb resolution, let
alone a genome-covering array (21), is beyond the reach of
most individual laboratories and as a consequence these
arrays have not been widely available. Nevertheless, the
BAC platform is outstandingly sensitive and precise.
OaCGH platforms are characterized by single-stranded
25 to 85mer oligonucleotide elements on the array. Different
oligo arrays are combined with different labeling and hybrid-
ization techniques and all yield high-resolution copy number
measurements.
Affymetrix is a commercial oaCGH platform, which con-
tains short 25mer oligonucleotides photo-lithograhically
synthesized on the arrays (http://www.affymetrix.com/)
(22). These are single channel arrays, which means that
only test DNA needs to be labeled and hybridized. The
labeling of the test sample involves a restriction enzyme
based complexity reduction procedure and requires 250 ng
of DNA. Complexity reduction precludes the use of sub
optimal DNA quality samples, as can be the case with DNA
from archival FFPE specimens. The variation per element on
the array is relatively high, which gets compensated by the
large amount of elements on the array, currently 250 000
(250K) per array. A series of normal reference samples
needs to be hybridized each time in parallel, which is used
to calculate the chromosomal copy number changes across the
entire genome, now implemented in the analysis program
dChip (23). A big advantage of the Affymetrix system com-
pared with any of the other systems is that SNPs are detected
in parallel, allowing allelotyping (24).
Another commercial oaCGH platform was introduced by
Agilent Technologies (25,26) (http://www.agilent.com/).
They evaluated their original expression arrays for this pur-
pose as well as arrays designed speciﬁcally for array CGH,
which include oligonucleotides covering intergenic regions.
Both Agilent array platforms constitute of 60mer oligonuc-
leotides which are synthesized on the arrays and can be pur-
chased with 200 K unique oligonucleotides on the array. The
labeling protocol is basically the one used for the cDNA arrays
(2) and requires 1 mg of input DNA which hampers the use
of small clinical samples. To overcome this problem, a PCR
ampliﬁcation procedure was developed allowing as little as
10 ng of input DNA. Apart from the necessity to do ampli-
ﬁcations of test and reference sample(s) in parallel, any
PCR-based DNA ampliﬁcation introduces some level of
additional variation (8) and adds to the overall cost of arrays.
The Agilent platform has already been proven highly valuable
in a lung cancer study (27).
A third oligonucleotide platform offered commercially
is by NimbleGen (http://www.nimblegen.com/). They
provide arrays containing 385 K oligonucleotides photo-
lithograhically synthesized on the array. The array production
is extremely ﬂexible such that each array produced can have a
different set of oligonucleotides on it. The oaCGH oligonuc-
leotides are designed to be isothermal and vary between 45
and 85 bp in length (28). For their labeling and hybridization
procedures, Nimblegene adopted essentially the same
conditions as Agilent (26) and the cDNA CGH platforms
(2). Lucito et al. (29) applied an alternative method for
labeling oaCGH arrays, which was applied for the NimbleGen
arrays as well as for 70mer spotted oaCGH. The method called
ROMA (representational oligonucleotide micro array ana-
lysis) impliesa98%complexityreductionoftestandreference
DNA. This is carried out by a digestion-ampliﬁcation step,
which allows starting with as little as 50 ng of input DNA.
To warrant reproducibility, this labeling and ampliﬁcation
procedure requires test and reference samples to be ampliﬁed
in parallel (8). ROMA combined with the NimbleGen array
provides a high-resolution alternative that allows low amounts
of sample DNA input and has already proven its value in the
ﬁeld of human genetics (30).
Afourth oaCGH platform isnon-commercial andmakesuse
of oligonucleotide libraries that are spotted as elements on the
arrays (13,14). Currently, 60–70mer libraries of 30 K are used
(14). A larger library of 50 K is currently being marketed,
which was designed with oaCGH in mind (see http://
alizadehlab.stanford.edu/). The labeling and hybridization
procedures adapted for these ‘in-house printed’ oaCGH arrays
is the one developed initially for the BAC arrays (18). This
hybridization procedure uses random primer labeling which
requires as little as 250 ng, which makes it very suitable for
direct labeling of DNA from clinical samples and the proced-
ure was proven to be functional for DNA of reduced quality,
such as that isolated from archival FFPE specimens (14,31).
The non-commercial in-house oaCGH platform has mean-
while proven its value in research (15). In our laboratories
in Amsterdam we successfully tested random primer labeling
combined with our hybridization procedures, on the 42 K
oaCGH arrays from Agilent (data not shown). So far, this
has worked for fresh DNA but not for DNA isolated from
FFPE material.
COMPETING FOR SPATIAL RESOLUTION
Array CGH has thus been developed to increase the spatial
resolution for the detection of chromosomal copy number
changes. Different platforms therefore compete based on this
spatial resolution. Spatial resolution is determined by the
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number of elements on the arrays, the chromosomal distribu-
tion of printed elements, the length of the elements as well
as the amplitude of a chromosomal copy number change.
Thus, the platform with the most and shortest array elements
with least variance that are most evenly distributed across the
genome and the most optimal sequence design has the best
resolution.
None of the current oaCGH platforms can make a deﬁnite
call for loss or gain using a single oligonucleotide, but rather
3–5 adjacent oligonucleotides are necessary for a reliable call
(Table 1). For the BAC arrays, it is proclaimed one can make
a call on a single arrayed element, such that after dye inten-
sity normalization a log2ratio of plus or minus 0.5 represents
a gain for the chromosomal region of the respective BAC.
Thus, although BAC arrays have relatively few printed
elements on the arrays, their spatial resolution is relatively
high. The maximal resolution that can be obtained with
BACs arrays, however, is ﬁnite because of their large size.
We would like to illustrate this with the following calculation:
a 150 kb BAC divided by the length of a 60 bp oligonucleotide
results in 2500 adjacent oligonucleotides within one BAC.
This would imply a 2500 times improved resolution. Practic-
ally, however, only unique oligonucleotide sequences will
perform well such that cross-hybridizing and repetitive
sequence elements need to be avoided in the design. Taking
both the repetitive sequences as well as oligonucleotide
sensitivity into account, we estimate that with oaCGH still
a resolution of roughly 500 times or higher compared with
BAC arrays can be obtained. Overlapping BACs can generate
sub-BAC resolution, but still cannot match the resolution
obtained by oligonucleotides.
PCR ampliﬁcation procedures reduce BACs to a mixture
of genomic sequences and can as such be regarded as a ‘not-
moving’ averaging window of 150–200 kb. Thus, a moving
average on oligonucleotides could effectively be seen as
the in silico synthesis of BACs, but providing repeated
measurements on independent array elements resulting in
reliable conﬁdence intervals. As an alternative to the compu-
tational combining of oligonucleotides to mimic a BAC, oli-
gonucleotides can be physically combined, but obviously
conﬁdence intervals are then lost.
In Table 1, the standard deviations of arrayed elements
on consecutive chromosomal positions are given for three
different platforms for which datasets were publicly available.
A standard deviation is used to illustrate how one could
compare the variation of the different oaCGH platforms and
(moving) averaging is used to give an impression how many
array elements are required to make a call on a single copy
number change. Non-overlapping standard deviations indicate
a single copy number change call can be made (14). The
amplitude of the single copy number change is platform
dependent and is given in Figure 1. Figure 1 and Table 1
are meant to illustrate how current platforms can be compared
with available raw data.
With regard to the CGH arrays one needs to be careful with
the use of the word ‘variation’ as opposed to ‘noise’, since
Table 1. Total variation expressed in standard deviation of raw log2-ratios for
chromosomes without copy number aberrations
Platform Cell line Chr. Log2ratio Dev.
Agilent CGH MB453 18q 0.6600
Agilent CGH MB453 2 0.6196
Agilent CGH MB453 2 0.3085*
In-house printed BT474
a 2 0.2442
In-house printed BT474
b 2 0.2514
In-house printed BT474
c 2 0.2498
In-house printed BT474
c 2 0.1480*
UCSF (BAC) MB453 2 0.1828
UCSF (BAC) BT474
a 2 0.1708
UCSF (BAC) BT474
b 2 0.1403
UCSF (BAC) BT474
c 2 0.1371
Therefore the raw data provided as Supplementary Data to the Agilent (25),
in-house printed (14) and UCSF BAC (18) arrays were used to calculate the
standard deviation of the ratio of at least 70 consecutive elements in a chro-
mosomal region without known copy number changes. Columns give, res-
pectively, platform [Agilent, In-house printed and UCSF BAC (18); a, b and
crepresenttheresultsfromthreeindependentarraysfromthatpublication],cell
line, chromosome (Chr.) and the data extracted from standard deviation
(Log2ratio Dev.) for the arrayed elements (BAC or oligonucleotides). Total
variationsmeasuredareratherconsistentforthedifferenthybridizationswithin
one platform; the BAC platform with the large insert clones displays a
considerable lower variation compared with the oligonucleotide platforms.
Asterisk illustrates the effect of pooling; pooling was performed by moving
the average of three arrayed elements before calculating standard deviations.
The Affymetrix, ROMA or NimbleGen platforms could not be included, since
raw log2 ratios were not available or comparable.
Figure 1. Relationbetweentheoreticalandmeasuredchromosomalcopynum-
ber changes for several different platforms. Number of chromosomes on the
horizontalaxis and the dye normalizedexperimentalratios on the verticalaxis.
Agilent custom oaCGH (25), speckled gray line with diamonds, slope 0.53;
BAC arrays (3), thin line with dots, slope 0.37; in-house printed oaCGH (14),
shortdasheslinewithplusses,slope0.28;AgilentoaCGHonexpressionarrays
(25), dark gray line with triangles slope 0.21. A single chromosomal copy gain
inadiploidbackgroundtheoreticallyshiftstheratiofrom1to1.5(twochromo-
somes/two chromosomes versus three chromosomes/two chromosomes). To
detect a single copy gain in a diploid background, the total variance should
therefore be smaller than 0.25 so that there is no overlap between normal and
gain. The copy number values and slope for the Agilent CGH platform (25) is
nearly identical to the theoretical values and slope. However, the variance for
one or even three array elements combined is too high to unequivocally call
a gain (Table 1). The relation between the theoretical and measured chromo-
somal copy number change for a given BAC array is slightly compressed, but
the variance is maximally 0.18 (Table 1). This makes it possible to make a call
onasinglearrayedBACelement.Forthein-houseprintedoaCGHplatformthe
relation between theoretical and measured chromosomal copy number is also
not ideal; however, three oligonucleotides are still sufficient to call a single
copynumberchange,sincetheelementshavea limitedvariance(Table1).The
ROMA or NimbleGen platforms could not be included, since raw log2 ratios
were not available. The Affymetrix (22) platform was not included since it is a
single channel array and this figure presents normalized ratios.
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is the technical noise combined with biological variation
consisting of segmental duplications and sequence variations
between individuals (32–34). The consequence for array CGH
of these sequence variations between individuals is discussed
in detail by Pinkel and Albertson (5). Repeated hybridizations
can separate the effects that sequence variation and technical
noise have on the total variation (Table 1), which was carried
outfor both the BAC CGH and in-house printed oaCGH arrays
using the BT474 cell line (14,18). BACs are less sensitive to
large sequence variations compared with oligonucleotides,
due to their length. The oligonucleotides, however, have the
advantage that the ﬂexibility in the design makes it possible
to either include or exclude regions that vary between indi-
viduals.Tothisend,informationonsequenceofahighnumber
of individuals needs to be obtained, which is now within our
reach with the introduction of massive parallel sequencing
(35). By excluding the biologically variable regions, the vari-
ation of oaCGH arrays can be reduced to technical noise,
which would reduce the total variation by a factor of 2 for
the in-house printed oligonucleotide platform (14). On the
other hand, by using oligos that cover variable loci, the
array CGH technique can be employed to measure these
copy number variations (22,33,36,37).
THE OPTIMAL LENGTH OF AN ARRAY
CGH ELEMENT
It is important to evaluate what the minimal length of an array
element is, which gives maximal performance. The ROMA
group has evaluated inﬂuence of the length of oligonucleotides
on variance from 30 to 70mers, and selected the 70mer as their
standard (29). Of all the oaCGH platforms currently available,
the short 25mer oligonucleotides on the Affymetrix arrays
produce the highest noise level per element (22). No synthetic
oligonucleotides longer than 85 bp (28) have been evaluated
since oligonucleotides become increasingly impure with
increasing length. A clue toward the sensitivity of arrays con-
taining oligonucleotides longer than 100 bp can be obtained
from the exon-arrays (10). Exon-arrays contain single-stranded
PCR products ranging in size from 139 to 571 bp, essentially
representing very long oligonucleotides, but with the same
high sensitivity per arrayed element as BACs. Based on the
fact that the 60–70mer ssDNA elements from the oligonuc-
leotide arrays display considerably more variation on the
CGH arrays compared with the 139mer ssDNA elements
from the exon arrays, we conclude that oligonucleotides of
140 bp would be preferable. Regretfully, the exon-array can-
not be produced on a genome-wide scale since they will by
deﬁnition be lacking all ‘agenic’ portions of the genome and
would be extremely labor intensive to produce (9). New devel-
opments for the synthesis of longer oligonucleotides are
underway and could offer an excellent solution (38).
ADDITIONAL CONSIDERATIONS
An important consideration when selecting an array CGH
platform is the price, especially when studying larger series
of samples. Cost of the arrays, as with expression arrays, can
be addressed as follows: in-house printed arrays are generally
cheaper than commercial arrays and increasing amounts of
elements on the array increase the price, whereby the resolu-
tion required is dependent on the research question. Further-
more, the amount of Cye dyes used for labeling reaction
seriously inﬂuences the price as well as the amount of
Cot-1 DNA.
Especially for diagnostic applications, standardization and
reproducibility are important issues. Synthetic oligonucleo-
tides obviously have the advantage that the exact sequence
and length is known for each element on the arrays. For PCR-
ampliﬁed BACs, this is not the case since the ampliﬁcation
procedure is not linear and variable for each ampliﬁcation
round (18,39). A second variable in array CGH is the Cot-1
DNA used to block repetitive DNA sequences in the arrayed
elements (5). Each time Cot-1 DNA is isolated it is extracted
from different human placentas and yields variable DNA frag-
ments of 50–300 bp in length. Batch to batch variation makes
Cot-1 DNA a highly variable element in the array procedure.
For oaCGH, Cot-1 DNA would theoretically not be necessary,
sincetheoligonucleotides aredesignedtoberepeat-free. Cot-1
DNA has been included in all array CGH platforms, except for
the NimbleGen arrays in which it was completely omitted
(28). Also in our experience (14) omitting Cot-1 DNA is
possible, but we observed a slight reduction in the quality
of the measurements using the in-house printed oaCGH
platform.
EXPECTATIONS
Based on the considerations discussed, odds are that the array
CGH ﬁeld is evolving towards oligonucleotide array CGH.
Today oaCGH offers the highest resolution and is therefore
slowly overtaking BAC arrays for the measurement of chro-
mosomal copy number changes in human genetics and
cancer. It is to be expected that the transition from BAC
CGH arrays to oaCGH will gradually take place, analogous
to the way cDNA arrays for expression proﬁling have been
replaced by oligonucleotide arrays. For speciﬁc applications
there will still be a place for BAC arrays, like in the case of
methylation studies (40).
Each platform has its own advantages and disadvantages
and arrays as well as protocols rapidly improve. Some oaCGH
platforms can handle degraded DNA samples, some offer
ultra-high density or are highly cost effective, others also
give SNP information or are ﬂexible in their design.
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